Ziopharm Oncology INC
SEC CIK 1107421 · ZIOP · last insider filing 2026-06-17
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Weis Holger | Director · Chief Executive Officer | filed 2021 - 2026 |
| Postma Robert W | Director | filed 2021 - 2026 |
| Vieser Jaime | Director | filed 2021 - 2026 |
| Jerman Michael Allen | Director | filed 2025 - 2026 |
| Hogue Dale Curtis Jr. | Director · See Remarks | filed 2024 - 2025 |
| Hofmeister Robert | Director | filed 2023 - 2024 |
| Boyle Kevin S. Sr. | Director · Chief Executive Officer | filed 2021 - 2023 |
| Thistle Mary | Director | filed 2020 - 2023 |
| Huang James | Director | filed 2020 - 2023 |
| Bowden Christopher | Director | filed 2019 - 2022 |
| Hagen Heidi | Director · Interim CEO | filed 2019 - 2021 |
| Buchi J Kevin | Director | filed 2020 - 2021 |
| Cooper Laurence James Neil | Director · President and CEO | filed 2015 - 2021 |
| Tarriff Scott | Director | filed 2015 - 2020 |
| Ezickson Elan | Director | filed 2018 - 2020 |
| Pagan Douglas W. | Director | filed 2018 - 2020 |
| Braunstein Scott | Director | filed 2018 - 2020 |
| Cannon James Anthony | Director | filed 2006 - 2019 |
| Kirk Randal J | Director | filed 2011 - 2018 |
| Weiser Michael | Director | filed 2006 - 2018 |
| Fowler Wyche | Director | filed 2006 - 2018 |
| Brennan Murray | Director | filed 2006 - 2018 |
| Mcinerney Timothy | Director | filed 2006 - 2015 |
| Lewis Jonathan | Director · CEO | filed 2006 - 2015 |
| Bagley Richard E | Director · President, COO & Treasurer | filed 2006 - 2012 |
| Abercrombie George B | Director | filed 2010 - 2010 |
| Fragin Gary S | Director | filed 2006 - 2010 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Groenewald Ferdinand | Vice President, Finance | filed 2024 - 2025 |
| Lackey Melinda | Senior Vice President, Legal | filed 2021 - 2025 |
| Wong Michael | Vice President, Finance | filed 2021 - 2023 |
| Deniger Drew | VP, Research and Development | filed 2022 - 2023 |
| Srivastava Abhishek K | See Remarks | filed 2022 - 2023 |
| De Groot Eleanor | EVP, Operations | filed 2019 - 2022 |
| Baffa Raffaele | Chief Medical Officer | filed 2021 - 2021 |
| Hadfield Robert | General Counsel and Secretary | filed 2018 - 2021 |
| Buck Jill | EVP, GM Gene Therapy | filed 2019 - 2021 |
| Cunningham Timothy M. | interim CFO | filed 2021 - 2021 |
| Lafond Kevin G | Vice Pres., Treasurer, & CAO | filed 2013 - 2021 |
| Mauney David M MD | President | filed 2017 - 2020 |
| Shukla Sath | EVP, Chief Financial Officer | filed 2019 - 2020 |
| Lebel Francois | Executive Vice President R&D | filed 2015 - 2018 |
| Belbel Caesar J | EVP, Chief Legal Officer & Sec | filed 2011 - 2018 |
| Amello Jason | Executive Vice President & CFO | filed 2012 - 2013 |
| Youssoufian Hagop | President of R&D and CMO | filed 2011 - 2013 |
| Schwartz Brian | V.P. Chief Medical Officer | filed 2008 - 2008 |
| Gale Robert Peter | Senior V.P. of Research | filed 2006 - 2006 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.